In LDM of 3T3-L1 adipocytes, Indinavir inhibited ATB-BMPA binding, with half-maximal inhibition values of 20.7±3.9 µM for GLUT4 and 178±43 µM for GLUT1. Indinavir did not inhibit cell fusion in co-cultured HL2/3 and HeLa-CD4-LTR-β-gal cells. In MDM co-cultures compared with control media, late Indinavir sulfate addition reduced transmission in each group. In sorted CD11c+ MDC co-cultures, Indinavir addition reduced p24+ T cells after co-culture with HIV-1–infected DCs compared with its absence. [1,2,3,4]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Glucose Transporter Binding in Adipocyte Membranes
Cell-based study · LDM of 3T3-L1 adipocytes [1]
LDM of 3T3-L1 adipocytes were treated with Indinavir. Half-maximal inhibition of ATB-BMPA binding occurred at 20.7±3.9 µM for GLUT4 and 178±43 µM for GLUT1.
Literature-Reported Treatment Conditions
- Exposure duration
- 10 min at room temperature
- Method
- added to 200 µg of LDM
- Vehicle
- water
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: Indinavir
The paper names Indinavir without stating the salt or form; not verified as the sulfate form supplied as A11871. No dose conversion or lot validation.
Materials and Methods > Materials (S7); Results > Effect of PIs on ATB-BMPA labeling and glucose uptake (S66); Figure 5 legend (S144, S145, S146, S148); Table 1 legend (S153, S156); Table 1 (T1.h1, T1.r1)
Half-maximal inhibition (IC50) for ATB-BMPA binding to GLUT4 and GLUT1: Half-maximal inhibition (IC50) for ATB-BMPA binding to GLUT4 and GLUT1; comparator: vehicle treated controls — Table 1 legend (S153, S156); Table 1 (T1.h1, T1.r1)
Cell Fusion in Co-cultured Cells
Cell-based study · HL2/3 cells; HeLa-CD4-LTR-β-gal cells [2]
Indinavir was evaluated in co-cultured HL2/3 and HeLa-CD4-LTR-β-gal cells. It did not inhibit cell fusion in this cell-based fusion assay.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h
- Method
- co-cultured
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Indinavir
The paper names Indinavir without stating the salt or form; not verified as the sulfate form supplied as A11871. No dose conversion or lot validation.
Results > Inhibition of Env/CD4-mediated membrane fusion (S19); Methods > Cell-based fusion assay (S62, S63, S64)
percentage of inhibition of HL2/3-HeLa CD4 cell fusion: percentage of inhibition of HL2/3-HeLa CD4 cell fusion; comparator: positive control of untreated cells — Results > Inhibition of Env/CD4-mediated membrane fusion (S19); Methods > Cell-based fusion assay (S64)
Transmission in MDM Co-cultures
Cell-based study · MDMs [3]
MDM co-cultures received Indinavir sulfate at 1 μM before CD4+ T cell addition, with control media as the comparator. In each group, late indinavir addition reduced transmission.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 2 hours prior to CD4+ T cell addition on day 7
- Method
- Co-cultures in some instances were treated
- Co-treatment
- Other interventions in this design: HIV-1 BaL 3 TCID50/cell; GM-CSF; autologous CD4+ T cells 3 cells/MDM; rhIL-2 5 ng/ml. Compound effect isolated by the comparison: indinavir or control media.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Indinavir sulfate; Compound label in the paper: Indinavir
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Siglec-mediated uptake of virions into the VCC enhances trans-infection of T lymphocytes (S137); Materials and methods > Macrophage-T cell trans-infection assay (S227, S229, S230, S232, S233, S234); Fig 9 legend (S301, S304)
% of total CD3+ cells staining for p24: % of total CD3+ cells staining for p24; comparator: control media — Results > Siglec-mediated uptake of virions into the VCC enhances trans-infection of T lymphocytes (S137); Fig 9 legend (S304)
Infection in Dendritic Cell Co-cultures
Cell-based study · Sorted CD11c+ MDCs [4]
Indinavir at 1 μM was added to co-cultures of sorted CD11c+ MDCs and autologous CD4+ T cells. Compared with its absence, Indinavir addition reduced p24+ T cells after co-culture with HIV-1–infected DCs.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 3.5 d
- Method
- added to the co-cultures
- Co-treatment
- Other interventions in this design: HIV-1BaL 1 μg p24/ml; SEB 0.2 μg/ml; GM-CSF 2 ng/ml; autologous CFSE-labeled CD4+ T cells. Compound effect isolated by the comparison: absence (A and B) or presence (C and D) of the protease inhibitor Indinavir.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Indinavir
The paper names Indinavir without stating the salt or form; not verified as the sulfate form supplied as A11871. No dose conversion or lot validation.
Results > Differential transfer of HIV-1BaL and HIV-1IIIB from MDCs and PDCs to CD4+ T cells (S42, S44); Materials and Methods > DC isolation (S133); Materials and Methods > HIV-1 infection and stimulation of DCs (S143); Materials and Methods > Isolation and CFSE labeling of CD4+ T cells (S158); Materials and Methods > Co-culture of HIV-1–infected DCs with autologous CD4+ T cells (S165, S167, S168); Materials and Methods > Analysis of a DC-mediated transfer of HIV-1 to antigen-specific T cell...
frequency of HIV-1 infection (intracellular p24 staining): frequency of HIV-1 infection (intracellular p24 staining); comparator: absence (A and B) — Results > Differential transfer of HIV-1BaL and HIV-1IIIB from MDCs and PDCs to CD4+ T cells (S44); Figure 3. legend (S208)